Mobusher Mahmud, MD
Interventional Cardiology · Lancaster, OHNPI 1558466227
Payments from drug & device makers
Across 117 payments — averaging $35.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Medtronic$576
- Novartis$222
- Johnson & Johnson$164
- Amgen$156
- Pfizer$118
- plus $686 from 22 others
Across 1 payment — averaging $258.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$259
What the payments were for
- Travel & lodging$1,91846%
- Food & beverage$2,21553%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 13 | $2,225 |
| Medtronic(2 entities) | 16 | $576 |
| Novartis | 15 | $222 |
| Johnson & Johnson | 11 | $164 |
| Amgen | 10 | $156 |
| Pfizer | 7 | $118 |
| Sanofi-aventis U.S. LLC | 7 | $92 |
| AstraZeneca(2 entities) | 5 | $73 |
| Bayer | 3 | $57 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $56 |
| Astellas Pharma US Inc | 3 | $43 |
| Novo Nordisk | 2 | $39 |
| Abiomed | 1 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Aurinia Pharma U.S., Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Bard Peripheral Vascular, Inc. | 1 | $20 |
| Bardy Diagnostics, Inc. | 1 | $20 |
| Ardelyx, Inc. | 1 | $19 |
| Avinger Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| AbbVie | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $16 |
| Baxter Healthcare | 1 | $15 |
| OPKO Pharmaceuticals, LLC | 1 | $13 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VersaCross Access Solution$1,763
- WATCHMAN FLX$143
- LINQ II$107
How this compares
$4,147 in reported general payments places this provider in the 40th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 345 | $263,502 |
| XareltoRivaroxaban | 204 | $183,272 |
| Repatha SureclickEvolocumab | 117 | $101,078 |
| BrilintaTicagrelor | 106 | $54,798 |
| Ranolazine ErRanolazine | 453 | $40,004 |
| Prasugrel Hcl | 204 | $25,638 |
| Repatha SyringeEvolocumab | 31 | $17,961 |
| Propafenone Hcl ErPropafenone Hcl | 68 | $14,689 |
| EntrestoSacubitril/Valsartan | 18 | $12,127 |
| Mexiletine Hcl | 100 | $5,806 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 488 | $5,420 |
| Propafenone Hcl | 110 | $4,544 |
| Olmesartan Medoxomil | 155 | $4,523 |
| Atorvastatin Calcium | 531 | $4,280 |
| Metoprolol Succinate | 388 | $3,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $118 | $263,502345 claims |
| Johnson & JohnsonXarelto | $164 | $183,272204 claims |
| AstraZenecaBrilinta | $73 | $54,798106 claims |
| NovartisEntresto | $222 | $12,12718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Lancaster
- Santiago GarciaCincinnati$3.6M
- Gary AnselColumbus$3.4M
- Dean KereiakesCincinnati$3.4M
- Steven YakubovColumbus$3.2M
- Joseph ChooCincinnati$1.9M
- Carlos Sanchez SotoColumbus$1.7M
- John CheathamColumbus$1.7M
- Brendan DuffyCanton$1.5M
- Timothy HenryCincinnati$1.3M
- Gary FishbeinCenterville$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.